Clinical trial · Observational
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data: An Initiative by the Korean Adrenal Disorder Study (KADS) Group
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. The approach involves building prospective and retrospective patient registries, which will be utilized to develop and conduct research on disease-specific protocols for adrenal disorders. The study targets patients with primary aldosteronism, pheochromocytoma, adrenal cancer, adrenal incidentalomas, and mild autonomous cortisol secretion. Registries for patients with adrenal diseases will be obtained from Seoul National University Hospital and Asan Medical Center, along with securing a common data model. The ultimate goal is to conduct research to generate clinical evidence for adrenal diseases using these resources.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adrenal Cortical Carcinoma | Adrenal Cortical Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Adrenal Tumor | Adrenal Gland Neoplasm | ALIAS | 0.90 |
| Cushing Syndrome | — | UNRESOLVED | — |
| Pheochromocytoma | Adrenal Gland Pheochromocytoma | ALIAS | 0.90 |
| Primary Aldosteronism | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (6)
- label
- Nonfunctioning adrenal adenoma
- description
- Incidentally detected adrenal mass without hormone production
- label
- Mild autonomous cortisol secretion
- description
- Adrenal tumors that do not meet the criteria for adrenal Cushing's syndrome but are not suppressed to below 1.8 µg/dL after the dexamethasone suppression test
- label
- Adrenal Cushing syndrome
- description
- Adrenal diseases characterized by biochemical hypercortisolism accompanying with overt Cushingoid features.
- label
- Primary aldosteronism
- description
- Adrenal diseases characterized by the excessive production of the hormone aldosterone and suppressed renin. Diagnostic criteria are as the following: 1. Plasma aldosterone level of ≥6 ng/dL after a seated saline infusion test 2. Plasma aldosterone level of ≥13 ng/dL after a captopril challenge test.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * patients with adrenal diseases such as adrenal cortical carcinoma, Cushing's syndrome, primary aldosteronism, pheochromocytoma, adrenal incidentaloma * patients who are 19 years or older Exclusion Criteria: * patients younger than 19 years old
References
Publications (0)
Data not yet available